Skip to main content

Genome Analysis and Characterisation of the Exopolysaccharide Produced by Bifidobacterium longum subsp. longum 35624™

  • 2016-09-22
  • PLOS ONE 11(9)
    • F. Altmann
    • P. Kosma
    • A. O’Callaghan
    • S. Leahy
    • F. Bottacini
    • Evelyn M. Molloy
    • S. Plattner
    • E. Schiavi
    • Marita Gleinser
    • D. Groeger
    • R. Grant
    • Noelia Rodriguez Perez
    • S. Healy
    • Elisabeth Svehla
    • Markus Windwarder
    • A. Hofinger
    • M. O'Connell Motherway
    • C. Akdis
    • Jun Xu
    • J. Roper
    • D. van Sinderen
    • L. O’Mahony

Abstract

The Bifibobacterium longum subsp. longum 35624™ strain (formerly named Bifidobacterium longum subsp. infantis) is a well described probiotic with clinical efficacy in Irritable Bowel Syndrome clinical trials and induces immunoregulatory effects in mice and in humans. This paper presents (a) the genome sequence of the organism allowing the assignment to its correct subspeciation longum; (b) a comparative genome assessment with other B. longum strains and (c) the molecular structure of the 35624 exopolysaccharide (EPS624). Comparative genome analysis of the 35624 strain with other B. longum strains determined that the sub-speciation of the strain is longum and revealed the presence of a 35624-specific gene cluster, predicted to encode the biosynthetic machinery for EPS624. Following isolation and acid treatment of the EPS, its chemical structure was determined using gas and liquid chromatography for sugar constituent and linkage analysis, electrospray and matrix assisted laser desorption ionization mass spectrometry for sequencing and NMR. The EPS consists of a branched hexasaccharide repeating unit containing two galactose and two glucose moieties, galacturonic acid and the unusual sugar 6-deoxy-L-talose. These data demonstrate that the B. longum 35624 strain has specific genetic features, one of which leads to the generation of a characteristic exopolysaccharide.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Bifidobacterium longum subsp. longumEnhanced Immune RegulationBeneficial
Moderate
Bifidobacterium longum subsp. longumImproved Irritable Bowel Syndrome SymptomsBeneficial
Moderate
Bifidobacterium longum subsp. longum 35624Reduced Irritable Bowel Syndrome SymptomsBeneficial
Moderate
Bifidobacterium longum subsp. longum UABI-14Improved Irritable Bowel Syndrome SymptomsBeneficial
Moderate
Bifidobacterium longum subsp. longum UABI-14Increased Regulatory T Cell CountBeneficial
Moderate

Pillser helps you make informed health decisions by providing comprehensive, unbiased information about supplements. This includes detailed research on supplement ingredients, their benefits, potential risks, and their overall efficacy. You can contribute by sharing your feedback and suggestions.

Send us an email at support@pillser.com.